GSK
GSK plc American Depositary Shares (Each representing two)
$50.98
+$1.17(+2.35%)
24
Overall
--
Value
27
Tech
21
Quality
Market Cap
$104.92B
Volume
3.46M
52W Range
$35.45 - $61.70
Target Price
$56.57
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $27.9B | $30.2B | $30.8B | $33.8B | $34.1B | $34.1B | $29.3B | $30.3B | $31.4B | $32.7B | ||
| Total Revenue | $27.9B | $30.2B | $30.8B | $33.8B | $34.1B | $34.1B | $29.3B | $30.3B | $31.4B | $32.7B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $9.3B | $10.3B | $10.2B | $11.9B | $7.9B | $8.2B | $9.6B | $8.6B | $9.0B | $9.0B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $18.6B | $19.8B | $20.6B | $21.9B | $16.4B | $16.5B | $19.8B | $21.8B | $22.3B | $23.6B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $12.6B | $13.8B | $13.5B | $15.6B | $16.2B | $15.8B | $13.0B | $15.0B | $15.2B | $15.7B | ||
| Research & Development | $3.6B | $4.5B | $3.9B | $4.6B | $5.1B | $5.3B | $2.6B | $6.2B | $6.4B | $7.5B | ||
| Research Expense | -- | -- | -- | -- | -- | -- | $2.6B | $3.3B | -- | -- | ||
| Selling, General & Administrative | $9.4B | $9.7B | $9.9B | $11.4B | $11.5B | $11.0B | $8.6B | $9.4B | $11.0B | $9.1B | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | $927.0M | $9.4B | $11.0B | $9.1B | ||
| General & Administrative Expenses | $9.4B | $9.7B | $9.9B | $11.4B | $11.5B | $11.0B | $7.7B | $8.5B | -- | -- | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | -- | $735.0M | $835.0M | -- | -- | ||
| Depreciation & Amortization | $-624.0M | -- | $-687.0M | -- | $-2.7B | $-562.0M | $2.1B | $2.2B | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | -- | $-1.5B | -- | $2.1B | $2.2B | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | $1.1B | $1.2B | -- | -- | ||
| Other Operating Expenses | $3.4B | $2.0B | $11.0M | -- | -- | $476.0M | $758.0M | $-590.0M | $-2.2B | $-895.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $6.0B | $6.1B | $7.1B | $6.3B | $6.2B | $6.7B | $5.7B | $6.7B | $7.1B | $7.9B | ||
| EBITDA | $2.7B | $4.3B | $5.5B | $7.1B | $8.1B | $6.5B | $8.6B | $6.9B | $7.2B | $8.1B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $717.0M | $737.0M | $694.0M | $879.0M | $847.0M | $764.0M | $826.0M | $792.0M | $669.0M | $701.0M | ||
| Intinc | $70.0M | $63.0M | $73.0M | $69.0M | $29.0M | $26.0M | $2.0M | $115.0M | $122.0M | $169.0M | ||
| Net Non-Operating Interest Income/Expense | $662.0M | $667.0M | $726.0M | $840.0M | $850.0M | $754.0M | $826.0M | $-677.0M | $-547.0M | $-532.0M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | $12.0M | -- | -- | -- | ||
| Other Income/Expense | -- | -- | -- | -- | -- | -- | $-3.2B | $6.0M | $-9.0M | $-1.0M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | $1.1B | $-1.0M | $6.0M | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $2.2B | $1.0B | $1.3B | $92.0M | $1.3B | $1.1B | -- | -- | -- | -- | ||
| Special Income Charges | $2.0B | $753.0M | $1.0B | $-873.0M | $-1.1B | $-96.0M | $-475.0M | $-468.0M | -- | -- | ||
| Impairment of Capital Assets | -- | $30.0M | -- | -- | -- | -- | $475.0M | $468.0M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $2.7B | $4.3B | $5.5B | $7.1B | $6.0B | $4.4B | $6.5B | $6.9B | $7.2B | $8.1B | ||
| Pre-Tax Income | $1.9B | $3.5B | $4.8B | $6.2B | $7.0B | $5.4B | $5.6B | $6.1B | $6.5B | $7.4B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $877.0M | $1.4B | $754.0M | $953.0M | $67.0M | $83.0M | $707.0M | $756.0M | $526.0M | $1.1B | ||
| NET INCOME | ||||||||||||
| Net Income | $912.0M | $1.5B | $3.6B | $4.6B | $5.7B | $4.4B | $15.0B | $4.9B | $5.6B | $5.7B | ||
| Net Income (Continuing Operations) | $1.1B | $2.2B | $4.0B | $5.3B | $6.4B | $5.1B | $4.9B | $5.3B | $6.0B | $6.3B | ||
| Net Income (Discontinued Operations) | $912.0M | $1.5B | $3.6B | $4.6B | $5.7B | $4.4B | $15.0B | $4.9B | $5.6B | $5.7B | ||
| Net Income (Common Stockholders) | $912.0M | $1.5B | $3.6B | $4.6B | $5.7B | $4.4B | $15.0B | $4.9B | $5.6B | $5.7B | ||
| Normalized Income | $3.5B | $3.6B | $4.9B | $4.2B | $4.5B | $4.3B | $3.2B | $4.5B | $6.5B | $7.3B | ||
| TOTALS | ||||||||||||
| Total Expenses | $-21.9B | $-24.1B | $-23.8B | $-27.5B | $-27.9B | $-27.4B | $22.6B | $23.6B | $24.3B | $24.7B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $3.1B | $3.1B | $3.1B | $3.2B | $3.2B | $3.2B | $4.0B | $405.2M | $407.7M | -- | ||
| Average Shares Outstanding (Diluted) | $3.1B | $3.2B | $3.2B | $3.2B | $3.2B | $3.2B | $4.1B | $411.1M | $414.2M | -- | ||
| Shares Outstanding | $4.3B | $4.0B | $4.0B | $4.0B | $4.0B | $4.0B | $5.0B | $2.0B | $2.0B | $4.3B | ||
| Basic EPS | $0.30 | $0.49 | $1.15 | $1.46 | $1.8 | $1.38 | $3.71 | $1.22 | $0.63 | -- | ||
| Basic EPS (Continuing Operations) | $0.30 | $0.49 | $1.15 | $1.46 | $1.8 | $1.38 | $3.71 | $1.22 | $0.63 | -- | ||
| Diluted EPS | $0.29 | $0.49 | $1.14 | $1.45 | $1.79 | $1.35 | $3.66 | $1.2 | $0.62 | -- | ||
| Diluted EPS (Continuing Operations) | $0.29 | $0.49 | $1.14 | $1.45 | $1.79 | $1.35 | $3.66 | $1.2 | $0.62 | -- | ||
| Dividend Per Share | $0.76 | $1.15 | $0.76 | $1.15 | $0.69 | $0.76 | $0.69 | $0.58 | $0.61 | -- | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | $2.61 | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | $2.57 | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | $-2.0M | $-5.0M | $3.0M | $1.0M | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | $-2.0M | $-5.0M | $3.0M | $1.0M | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | $1.8B | $-730.0M | $6.0M | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | $215.0M | -- | -- | -- | ||
| Minority Interests | $150.0M | $637.0M | $423.0M | $623.0M | $-639.0M | $-711.0M | $-665.0M | $-380.0M | $-376.0M | $-573.0M | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | $10.7B | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | $9.6B | $8.6B | $9.0B | $9.0B | ||
| Other Gand A | $9.4B | $9.7B | $9.9B | $11.4B | $11.5B | $11.0B | $7.7B | $8.5B | -- | -- | ||
| Write Off | $47.0M | $30.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | $-283.0M | $-289.0M | $-209.0M | $-965.0M | $-2.4B | $-1.2B | -- | -- | -- | -- | ||
| Restruct | $2.2B | $1.0B | $1.3B | $92.0M | $1.3B | $1.1B | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GSK | $50.98 | +2.3% | 3.46M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get GSK plc American Depositary Shares (Each representing two) Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW